Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 255

Related Citations for PubMed (Select 19895781)

1.

Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.

Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB.

J Clin Psychiatry. 2010 Feb;71(2):103-8. doi: 10.4088/JCP.08m04818yel. Epub 2009 Nov 3.

PMID:
19895781
2.

Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.

Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ.

Clin Ther. 2007 Jan;29(1):183-95.

PMID:
17379060
3.

Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims.

Lambert BL, Chou CH, Chang KY, Tafesse E, Carson W.

Pharmacoepidemiol Drug Saf. 2005 Jun;14(6):417-25.

PMID:
15786516
4.

Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia.

Tiihonen J, Suokas JT, Suvisaari JM, Haukka J, Korhonen P.

Arch Gen Psychiatry. 2012 May;69(5):476-83. doi: 10.1001/archgenpsychiatry.2011.1532.

PMID:
22566579
5.

11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).

Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J.

Lancet. 2009 Aug 22;374(9690):620-7. doi: 10.1016/S0140-6736(09)60742-X.

PMID:
19595447
7.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
8.

Hyperlipidemia following treatment with antipsychotic medications.

Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ.

Am J Psychiatry. 2006 Oct;163(10):1821-5.

PMID:
17012695
9.

Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia.

Lambert BL, Chang KY, Tafesse E, Carson W.

J Clin Psychopharmacol. 2005 Feb;25(1):12-8.

PMID:
15643095
10.

Risk of hospitalization for acute pancreatitis associated with conventional and atypical antipsychotics: a population-based case-control study.

Gasse C, Jacobsen J, Pedersen L, Mortensen PB, Nørgaard M, Sørensen HT, Johnsen SP.

Pharmacotherapy. 2008 Jan;28(1):27-34.

PMID:
18154471
11.

Mortality risk in patients with schizophrenia participating in premarketing atypical antipsychotic clinical trials.

Khan A, Schwartz K, Stern C, Redding N, Kolts RL, Brown WA, Robinson DS.

J Clin Psychiatry. 2007 Dec;68(12):1828-33.

PMID:
18162012
12.

An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients.

Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, Revicki D, Buchanan RW.

Arch Gen Psychiatry. 2002 Nov;59(11):1021-6.

PMID:
12418935
13.

[Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].

Rubio G, Gómez-de-la-Cámara A, Ledesma F, Burón JA, Rodríguez-Morales A, Martínez-Junquera G; Grupo Español para el Estudio de la Diabetes en Pacientes Esquizofrénicos.

Med Clin (Barc). 2006 Apr 1;126(12):441-4. Spanish.

PMID:
16620729
14.

Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC.

J Clin Psychiatry. 2004 Oct;65(10):1377-88.

PMID:
15491242
15.

Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients.

Citrome L, Jaffe A, Levine J, Allingham B, Robinson J.

Psychiatr Serv. 2004 Sep;55(9):1006-13.

PMID:
15345760
17.

Antipsychotics and the risk of sudden cardiac death.

Straus SM, Bleumink GS, Dieleman JP, van der Lei J, 't Jong GW, Kingma JH, Sturkenboom MC, Stricker BH.

Arch Intern Med. 2004 Jun 28;164(12):1293-7. Erratum in: Arch Intern Med. 2004 Sep 27;164(17):1839.

PMID:
15226162
18.

All-cause mortality associated with atypical and typical antipsychotics in demented outpatients.

Trifirò G, Verhamme KM, Ziere G, Caputi AP, Ch Stricker BH, Sturkenboom MC.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):538-44.

PMID:
17036366
19.

Somnolence effects of antipsychotic medications and the risk of unintentional injury.

Said Q, Gutterman EM, Kim MS, Firth SD, Whitehead R, Brixner D.

Pharmacoepidemiol Drug Saf. 2008 Apr;17(4):354-64. doi: 10.1002/pds.1559.

PMID:
18314925
20.

Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada.

Curkendall SM, Mo J, Glasser DB, Rose Stang M, Jones JK.

J Clin Psychiatry. 2004 May;65(5):715-20.

PMID:
15163261
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk